Replies to post #101350 on Elite Pharmaceuticals Inc (ELTP)

[Steges]

We will have to disagree on that one. But surely as Drs. we can ought to agree this is a pretty remarkable tech, no? http://www.elitepharma.com/How_AR_Tech_Works.pdf

[Couch]

We investors here know that is mistaken. After all, Pfizer purchased Alpharma's already ran patents knowing they were already ran having to pay Purdue millions in royalty fees and still purchased them anyway. Elite's Patents are superior to Pfizer's and Nasrat and the existing data tells us so. ButI'll include some solid DD for new investors to read on the topic.

http://seekingalpha.com/instablog/4199131-couch/1941422-elite-pharmaceuticals-eltp-intellectual-property-ip-and-the-right-to-devise-a-better-pain-killer

It is when you understand the immense financial value of Elite's patented Intellectual Property (IP) along with the aforementioned push to curb the nations' prescription abuse epidemic and depending on how Congress and the FDA move, it would seem Elite could easily be in the midst of the Perfect Storm that is already brewing in the abuse deterrent space.

Elite has previously been given the green light to commence Ph3 trials with their signature once daily oxycodone/naltrexone product. Should Elite be able to pass Ph3 trails, this would be a Game Changer in and of itself. However, when you consider Elite's IP rights for their patented Abuse Resistant Technology (ART), its licensing potential, and the ability to put out multiple abuse resistant products, generic and branded, then the possibilities become absolutely staggering. This staggering possibility is better understood when you realize that shares bought now before trials begin have the real potential to set one up for a really nice financial windfall within the next few years. After all, Elite has technology that is going to give Purdue and Pfizer a run for their money in the abuse deterrent/resistant opioid space.